{"id":"optimised-dose-rifampicin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Drug-drug interactions"}]},"_chembl":{"chemblId":"CHEMBL374478","moleculeType":"Small molecule","molecularWeight":"822.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifampicin is a well-established antibiotic that binds to bacterial RNA polymerase, blocking transcription and translation in mycobacteria. The optimised dosing regimen aims to improve pharmacokinetic exposure and efficacy while maintaining tolerability in tuberculosis treatment. This approach seeks to enhance bacterial killing and potentially shorten treatment duration.","oneSentence":"Optimised dose rifampicin inhibits bacterial RNA polymerase to suppress mycobacterial protein synthesis and growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:36.209Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (optimised dosing regimen)"}]},"trialDetails":[{"nctId":"NCT07467252","phase":"PHASE2","title":"AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT","status":"NOT_YET_RECRUITING","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2026-09","conditions":"Pulmonary Tuberculosis","enrollment":200},{"nctId":"NCT06057519","phase":"PHASE3","title":"Pragmatic Optimized Rifampicin Trial","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2024-01-16","conditions":"Tuberculosis, Pulmonary","enrollment":164},{"nctId":"NCT05807399","phase":"PHASE2","title":"PanACEA - STEP2C -01","status":"RECRUITING","sponsor":"Michael Hoelscher","startDate":"2023-04-14","conditions":"Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis","enrollment":390},{"nctId":"NCT05575518","phase":"PHASE3","title":"A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"Stellah Mpagama","startDate":"2023-08-11","conditions":"Tuberculosis, Human Immunodeficiency Virus","enrollment":414}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Optimised dose rifampicin","genericName":"Optimised dose rifampicin","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifampicin is a small molecule that inhibits bacterial DNA-directed RNA polymerase, classified as an inhibitor. It is being studied in clinical trials, including the Pragmatic Optimized Rifampicin Trial (PORT), for its safety and tolerability in treating conditions such as tuberculosis and pulmonary tuberculosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}